In July 2009, the US Food and Drug Administration (USFDA) approved Eli Lilly and Merck’s cetuximab (Erbitux) for treatment of metastatic colorectal cancer and head and neck cancer. Head and neck cancer presents a significant public health challenge in India, with a staggering annual incidence of over 100,000 new cases.
